Pharmaceutical industry and university create Manchester Collaborative Centre for Inflammation Research

13 May 2011

GlaxoSmithKline (GSK), The University of Manchester, and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research (MCCIR), a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out w ith an initial investment of Â£5M from each partner over a three year period.

The collaboration between two UK-based pharmaceutical companies, GSK and AstraZeneca, and The University of Manchester, a premier research-led institution, will bring together scientists from both the pharmaceutical industry and academia to work collaboratively on inflammation research and translational medicine.

Scientists will be recruited for new positions to direct the research in line with strategic priorities set jointly by GSK, AstraZeneca and The University of Manchester, with the ultimate goal of translating findings into new and improved treatments. Such advances could potentially benefit the millions of people worldwide affected by diseases associated with chronic inflammation, including asthma, chronic obstructive pulmonary disease, rheumatoid arthritis and inflammatory bowel disease